Infographic: Statins not prescribed in two thirds of high-risk patients

Prescribing of statins in high-risk patients has decreased despite the lowering of the recommended initiation threshold, whilst patients in low-risk categories are being overtreated, a new study reveals.

Researchers at the University of Birmingham have shown that statins are usually prescribed without recording of the QRISK2 cardiovascular risk assessment score recommended by NICE. Even when a score is documented, the majority of high-risk patients do not receive statins.

Samuel Finnikin and colleagues analysed GP prescribing data for 1.4 million adults from 248 practices across the UK between January 2000 and December 2015, to examine the relationship between cardiovascular risk scoring and the initiation of statins in primary care.

Although the researchers found there was a steady increase in the recording of QRISK2 score since 2012, when the tool became available, 72.9% of patients initiated on statins did not have a score recorded. Of those who did, only 35% of patients in the high-risk category were put on a statin. Conversely, one in six statin initiations were in patients in the low-risk category, indicating significant overtreatment in this group. 

The researchers also investigated the effect on statin prescribing of the 2014 NICE guidance on lipid modification, which halved the recommended threshold for statin initiation to include patients with a 10% risk of developing cardiovascular disease over 10 years. 

When comparing data in the 18 months before and after publication of the guidance, the study found that the rate of statin initiation among patients in the intermediate-risk category increased while the rate among high-risk patients continued to decrease.

‘It is not possible to establish whether those patients who were above the threshold to be prescribed a statin did not receive treatment because they were not offered it or because they declined an offer,’ noted the researchers.  

Shared decision

Professor Helen Stokes-Lampard, chair of the RCGP, called the study 'interesting' but said it 'simplifies the true situation' because it did not consider individual patient circumstances that influence statin prescribing, such as patient preference and comorbidities.

However, she said the study 'emphasises the importance of calculating an accurate risk score which can then help healthcare professionals have an honest discussion with their patients about the benefits and risks which are unique to them.'

'As with any drug, taking statin medication has potential side-effects, and taking any medication long-term is a substantial undertaking for patients who need to be monitored by healthcare professionals. Many don’t want to take statins once they have learned all the facts – and GPs will respect patient choice,’ she added.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)